Search

Displaying results 2761 - 2770 of 2960 in total
  1. Drug

    Pacritinib

    go.drugbank.com/drugs/DB11697
    ApprovedInvestigational

    Pacritinib is an inhibitor of both wild-type and mutant (V617F) JAK2, as well as FMS-like tyrosine kinase 3 (FLT3), which was granted accelerated approval by the FDA in February 2022 for the treatment

  2. Drug

    Zavegepant

    go.drugbank.com/drugs/DB15688
    ApprovedInvestigational

    [A258190,A258195] In March 2023, the FDA approved the use of zavegepant nasal spray for the acute treatment of migraine with or without aura in adults.

  3. Drug

    Loprazolam

    go.drugbank.com/drugs/DB13643
    Experimental

    It is not an FDA-approved drug.

  4. Drug

    CTS-21166

    go.drugbank.com/drugs/DB06073
    Investigational

    CTS-21166 is the only BACE1 inhibitor that has passed Phase I clinical trial thus far.

  5. Drug

    CYT007-TNFQb

    go.drugbank.com/drugs/DB05758
    Experimental

    CYT007-TNFQb is an active immunization therapy that aims at providing a novel treatment to people suffering from RA or psoriasis.

  6. Drug

    Pyrethrum extract

    go.drugbank.com/drugs/DB11087
    Approved

    Pyrethrum is the crude extract form obtained from flowers of the plant Chrysanthemum cinerariifolium. Pyrethrin refers to a more refined extract of pyrethrum. While pyrethrum extract is composed of 6 esters, both organic compounds mediat...

    Mixtures: El piojito Lice Killing
  7. Drug

    Margetuximab

    go.drugbank.com/drugs/DB14967
    ApprovedInvestigational

    [A225751, A225756, A225766, A191829, L27986] Margextuximab was granted FDA approval on December 16, 2020, and is currently marketed under the trademark MARGENZA™ by MacroGenics, Inc.[L27986]

  8. Drug

    Tafasitamab

    go.drugbank.com/drugs/DB15044
    ApprovedInvestigational

    [L15292] Having previously received Breakthrough Therapy, Fast Track, and Orphan designations from the FDA,[A191829] tafasatimab-cxix (Monjuvi®) received an accelerated approval on July 31st, 2020,

  9. Drug

    Eflapegrastim

    go.drugbank.com/drugs/DB15001
    ApprovedInvestigational

    [L43135] In September 2022, eflapegrastim was approved by the US FDA as a prophylactic against infection, as manifested by febrile neutropenia, in patients receiving certain myelosuppressive anti-cancer

  10. Drug

    Cetyl alcohol

    go.drugbank.com/drugs/DB09494
    Approved

    According to the FDA Code of Federal Regulations, cetyl alcohol is a safe synthetic fatty acid in food and in the synthesis of food components under the condition that it contain not less than 98 percent